IBS News

Subscribe to IBS News feed
IBS Patient Group Community - IBSpatient.org - IBS News
Updated: 7 min 59 sec ago

Google-Diminished conditioned pain modulation observed in patients with IBS

Sep 14, 2018
Diminished conditioned pain modulation observed in patients with IBS Healio Full coverage View the full article

Google-Bacteria in Your Gut That Can Cause Diarrhea Can Also Generate Electricity

Sep 13, 2018
Bacteria in Your Gut That Can Cause Diarrhea Can Also Generate Electricity Fortune Frequent Diarrhea-Causing Bacterium Found out to Fabricate Electricity Newsline Full coverage View the full article

Twitter-Jersey City FODMAP workshop rescheduled for November 12. Hope you've got the day off for Veteran's Day and can register now! #RDN #NYC #greaterNYC #6CPE. Great location next to PATH https://t.co/teTMricNHs https://t.co/FVXhJhPezJ

Sep 13, 2018
Jersey City FODMAP workshop rescheduled for November 12. Hope you've got the day off for Veteran's Day and can register now! #RDN #NYC #greaterNYC #6CPE. Great location next to PATH https://www.ibsfree.net/fodmap-events/jerseycity (RSS generated with FetchRss) View the full article

Twitter-Live Q and A with Dr Douglas Drossman live from North Carolina- pre hurricane Florence! Stress and GI symptoms- they go together! https://t.co/MjX4PkmDfW

Sep 13, 2018
Live Q and A with Dr Douglas Drossman live from North Carolina- pre hurricane Florence! Stress and GI symptoms- they go together! https://www.facebook.com/RomeFoundation/videos/237126826976956/ (RSS generated with FetchRss) View the full article

Twitter-RT @DDrossman: Chronic #IBS or Abdominal Pain? Ten Tips for Self-Management https://t.co/I1fRtYmVH4

Sep 13, 2018
RT @DDrossman: Chronic #IBS or Abdominal Pain? Ten Tips for Self-Management http://drossmancenter.com/chronic-ibs-abdominal-pain-ten-tips-self-management-dr-drossman/ (RSS generated with FetchRss) View the full article

Google-Innomane Inc. Announces Health Canada Approval and Canadian Launch of Diaronex®, an Over-The-Counter Herbal ...

Sep 13, 2018
Innomane Inc. Announces Health Canada Approval and Canadian Launch of Diaronex®, an Over-The-Counter Herbal ... Canada NewsWire (press release) Full coverage View the full article

Google-Does Eating Banana Cause Or Relieve Constipation?

Sep 13, 2018
Does Eating Banana Cause Or Relieve Constipation? The Sentinel News (satire) (press release) (blog) Full coverage View the full article

Google-Ardelyx (ARDX) Submits NDA for US Marketing Authorization of Tenapanor for IBS-C to FDA

Sep 13, 2018
Ardelyx (ARDX) Submits NDA for US Marketing Authorization of Tenapanor for IBS-C to FDA StreetInsider.com Full coverage View the full article

Pubmed-Isotretinoin in retrospect.

Sep 13, 2018
Related Articles Isotretinoin in retrospect. Clin Dermatol. 2017 May - Jun;35(3):335-339 Authors: Karadag AS, Parish LC, Lambert WC PMID: 28511833 [PubMed - indexed for MEDLINE] View the full article

Pubmed-Systematic review and meta-analysis: conditioned pain modulation in patients with the irritable bowel syndrome.

Sep 13, 2018
Related Articles Systematic review and meta-analysis: conditioned pain modulation in patients with the irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Sep 11;: Authors: Albusoda A, Ruffle JK, Friis KA, Gysan MR, Drewes AM, Aziz Q, Farmer AD Abstract BACKGROUND: Irritable bowel syndrome (IBS) is common and is characterised by recurrent abdominal pain, which is a major contributor to healthcare seeking. The neurobiological basis of this pain is incompletely understood. Conditioned pain modulation is a neuromodulatory mechanism through which the brain inhibits the nociceptive afferent barrage through the descending pathways. Reduced conditioned pain modulation has been implicated in the pathophysiology of IBS, although to date only in studies with relatively small sample sizes. AIM: To clarify the relationship between conditioned pain modulation and IBS by undertaking a systemic review and meta-analysis METHODS: A systematic review of MEDLINE and Web of Science databases was searched (up to 10 May 2018). We included studies examining conditioned pain modulation in adults with IBS and healthy subjects. Data were pooled for meta-analysis to calculate the odds ratio and effect size of abnormal conditioned pain modulation in IBS, with 95% confidence intervals (CI). RESULTS: The search strategy identified 645 studies, of which 13 were relevant and 12 met the inclusion criteria. Conditioned pain modulation in IBS patients vs healthy subjects was significantly reduced, odds ratio 4.84 (95% CI: 2.19-10.71, P < 0.0001), Hedges' g effect size of 0.85 (95% CI: 0.42-1.28, P < 0.001). There was significant heterogeneity in effect sizes (Q-test χ2 = 52, P < 0.001, I2 = 78.8%) in the absence of publication bias. CONCLUSIONS: Conditioned pain modulation is significantly diminished in patients with IBS vs healthy controls. These data suggest that abnormal descending pathways may play an important pathophysiological role in IBS, which could represent an investigation and a therapeutic target in IBS. PMID: 30206948 [PubMed - as supplied by publisher] View the full article

Pubmed-Naturopathic Approaches to Irritable Bowel Syndrome-A Delphi Study.

Sep 13, 2018
Naturopathic Approaches to Irritable Bowel Syndrome-A Delphi Study. J Altern Complement Med. 2018 Sep 12;: Authors: Goldenberg JZ, Ward L, Day A, Cooley K Abstract INTRODUCTION: Irritable bowel syndrome (IBS) affects 11% of the population, and up to 50% of patients report using complementary and alternative medicines (CAM) for it. To date, there is no research describing how providers of naturopathic medicine in North America, a well-defined CAM profession, approach IBS. METHODS: A Delphi study was conducted over a 17-month period in 4 rounds with 15 North American naturopathic medicine experts in IBS. Consensus was defined as a median value of 75% or greater agreement with the relevant statement. RESULTS: Consensus was met with 45 statements describing a "reasonable naturopathic approach" to IBS. These statements covered the domains of general, office visits, tracking progress, testing, interventions, and resources. CONCLUSION: These results represent the beginning of an evidence base depicting naturopathic interventions for IBS and should inform future randomized controlled clinical trials in this area. Future research should look to reflect on and revise these guidance consensus statements particularly extending to other stakeholders as well as geographic and regulatory jurisdictions in the naturopathic profession. PMID: 30207740 [PubMed - as supplied by publisher] View the full article

Twitter-Make your voice heard in Washington! Email your story of how you or a loved one has been impacted by a #FGIMD to herzog@hmcw.org and we'll hand deliver your story to your Member of Congress to demonstrate the need 4 research through #HR1187. Toget

Sep 12, 2018
Make your voice heard in Washington! Email your story of how you or a loved one has been impacted by a #FGIMD to herzog@hmcw.org and we'll hand deliver your story to your Member of Congress to demonstrate the need 4 research through #HR1187. Together, we can make a difference! (RSS generated with FetchRss) View the full article

Google-RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D

Sep 12, 2018
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D GlobeNewswire (press release) RedHill Biopharma up 7% on announcing positive End-of-Phase II meeting with FDA on BEKINDA for IBS-D Seeking Alpha RedHill Biopharma (RDHL) Concludes Positive End-of-Phase II/Pre-Phase III Meeting with FDA on BEKINDA StreetInsider.com Full coverage View the full article

Pubmed-Neuropsychiatric Disorders: Influence of Gut Microbe to Brain Signalling.

Sep 12, 2018
Related Articles Neuropsychiatric Disorders: Influence of Gut Microbe to Brain Signalling. Diseases. 2018 Sep 06;6(3): Authors: Scriven M, Dinan TG, Cryan JF, Wall M Abstract The microbiome gut brain (MGB) axis consists of bidirectional routes of communication between the gut and the brain. It has emerged as a potential therapeutic target for multiple medical specialties including psychiatry. Significant numbers of preclinical trials have taken place with some transitioning to clinical studies in more recent years. Some positive results have been reported secondary to probiotic administration in both healthy populations and specific patient groups. This review aims to summarise the current understanding of the MGB axis and the preclinical and clinical findings relevant to psychiatry. Significant differences have been identified between the microbiome of patients with a diagnosis of depressive disorder and healthy controls. Similar findings have occurred in patients diagnosed with bipolar affective disorder and irritable bowel syndrome. A probiotic containing Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium bifidum produced a clinically measurable symptom improvement in patients with depressive disorder. To date, some promising results have suggested that probiotics could play a role in the treatment of stress-related psychiatric disease. However, more well-controlled clinical trials are required to determine which clinical conditions are likely to benefit most significantly from this novel approach. PMID: 30200574 [PubMed] View the full article

Pubmed-Applicability of Yeast Fermentation to Reduce Fructans and Other FODMAPs.

Sep 12, 2018
Related Articles Applicability of Yeast Fermentation to Reduce Fructans and Other FODMAPs. Nutrients. 2018 Sep 06;10(9): Authors: Fraberger V, Call LM, Domig KJ, D'Amico S Abstract A diet low in fermentable oligosaccharides, disaccharides, monosaccharides and, polyols (FODMAPs) is recommended for people affected by irritable bowel syndrome (IBS) and non-coeliac wheat sensitivity (NCWS) in order to reduce symptoms. Therefore, the aim of this study was to evaluate the impact of 13 sourdough-related yeasts on FODMAP degradation, especially fructans. First, a model system containing a typical wheat carbohydrate profile was applied to evaluate the growth rate of each yeast strain. Additionally, changes in the sugar composition, for up to four days, were monitored by high-pressure anion-exchange chromatography (HPAEC). A more realistic approach with a wheat flour suspension was used to characterize CO₂ production according to the Einhorn method. The reduction of the total fructans was analyzed using an enzymatic method. Furthermore, a fingerprint of the present fructans with different degrees of polymerization was analyzed by HPAEC. The results revealed strong differences in the examined yeast strains' ability to degrade fructans, in both the model system and wheat flour. Overall, Saccharomycescerevisiae isolated from Austrian traditional sourdough showed the highest degree of degradation of the total fructan content and the highest gas building capacity, followed by Torulasporadelbrueckii. Hence, this study provides novel knowledge about the FODMAP conversion of yeast strains. PMID: 30200589 [PubMed - in process] View the full article

Pubmed-Relationships Between Temporomandibular Disorders, MSD Conditions, and Mental Health Comorbidities: Findings from the Veterans Musculoskeletal Disorders Cohort.

Sep 12, 2018
Related Articles Relationships Between Temporomandibular Disorders, MSD Conditions, and Mental Health Comorbidities: Findings from the Veterans Musculoskeletal Disorders Cohort. Pain Med. 2018 Sep 01;19(suppl_1):S61-S68 Authors: Fenton BT, Goulet JL, Bair MJ, Cowley T, Kerns RD Abstract Objective: Temporomandibular disorders (TMDs) have been associated with other chronic painful conditions (e.g., fibromyalgia, headache) and suicide and mood disorders. Here we examined musculoskeletal, painful, and mental health comorbidities in men vs women veterans with TMD (compared with non-TMD musculoskeletal disorders [MSDs] cases), as well as comorbidity patterns within TMD cases. Design: Observational cohort. Setting: National Veterans Health Administration. Subjects: A cohort of 4.1 million veterans having 1+ MSDs, entering the cohort between 2001 and 2011. Methods: Chi-square tests, t tests, and logistic regression were utilized for cross-sectional analysis. Results: Among veterans with any MSD, those with TMD were younger and more likely to be women. The association of TMD with race/ethnicity differed by sex. Odds of TMD were higher in men of Hispanic ethnicity (OR = 1.38, 95% CI = 1.27-1.48) and nonwhite race/ethnicity other than black or Hispanic (OR = 1.29, 95% CI = 1.16-1.45) compared with white men. Odds of TMD were significantly lower for black (OR = 0.54, 95% CI = 0.49-0.60) and Hispanic women (OR = 0.84, 95% CI = 0.73-0.995) relative to white women. Non-MSD comorbidities (e.g., irritable bowel syndrome, mental health, headaches) were significantly associated with TMD in male veterans; their pattern was similar in women. Veterans with back pain, nontraumatic joint disorder, or osteoarthritis had more MSD multimorbidity than those with TMD. Conclusions: Complex patterns of comorbidity in TMD cases may indicate different underlying mechanisms of association in subgroups or phenotypes, thereby suggesting multiple targets to improve TMD. Longitudinal comprehensive studies powered to look at sex and racial/ethnic groupings are needed to identify targets to personalize care. PMID: 30203016 [PubMed - in process] View the full article

Pubmed-Elobixibat for the Treatment of Constipation.

Sep 12, 2018
Elobixibat for the Treatment of Constipation. Expert Rev Gastroenterol Hepatol. 2018 Sep 11;: Authors: Chedid V, Vijayvargiya P, Camilleri M Abstract INTRODUCTION: Chronic idiopathic constipation (CC) is highly prevalent worldwide. A subset of patients with CC have reduced fecal (and by inference, intra-colonic) bile acids (BA). Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC. BAs accelerate colonic transit and increase colonic secretion. Therefore, IBAT inhibitors have potential to treat patients with CC. Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor. In humans, elobixibat accelerated colonic transit. In phase 2A, 2B and 3 studies in CC, elobixibat was efficacious, well tolerated and safe. An open-label, phase 3 trial (52 weeks) confirmed the safety of elobixibat. Elobixibat reduces LDL cholesterol, increases serum GLP-1, and has potential in metabolic syndrome. Expert commentary: Uniquely among current treatments of CC, elobixibat stimulates both motor and secretory functions in the colon. These dual effects suggest that, when approved, elobixibat may be a first-line choice for constipation associated with colonic BA deficiency and a second-line treatment for all patients with CC and constipation-predominant irritable bowel syndrome. Further studies are required to confirm efficacy for relief of CC. Once approved, elobixibat will likely become a second-line choice for treatment of CC. PMID: 30204504 [PubMed - as supplied by publisher] View the full article

Google-My Bouts with Diarrhea Are a Time of Great Loathing

Sep 11, 2018
My Bouts with Diarrhea Are a Time of Great Loathing SMA News Today Full coverage View the full article

Google-Does Eating Banana Cause Or Relieve Constipation? We Find Out!

Sep 11, 2018
Does Eating Banana Cause Or Relieve Constipation? We Find Out! NDTV Full coverage View the full article

Pubmed-From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Sep 11, 2018
Related Articles From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018 Sep 07;24(33):3681-3694 Authors: Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F Abstract Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. We carried out a comprehensive literature review of the most relevant FC-related topics: the role of FC in discriminating between IBD and irritable bowel syndrome (IBS) and its use in managing IBD patients In patients with intestinal symptoms, due to the high negative predictive value a normal FC level reliably rules out active IBD. In IBD patients a correlation with both mucosal healing and histology was found, and there is increasing evidence that FC assessment can be helpful in monitoring disease activity and response to therapy as well as in predicting relapse, post-operative recurrence or pouchitis. Recently, its use in the context of a treat-to-target approach led to a better outcome than clinically-based therapy adjustment in patients with early Crohn's disease. In conclusion, FC measurement represents a cheap, safe and reliable test, easy to perform and with a good reproducibility. The main concerns are still related to the choice of the optimal cut-off, both for differentiating IBD from IBS, and for the management of IBD patients. PMID: 30197475 [PubMed - in process] View the full article

Pages